Literature DB >> 24764208

Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.

Ken-ichi Okada1, Manabu Kawai, Masaji Tani, Seiko Hirono, Motoki Miyazawa, Atsushi Shimizu, Yuji Kitahata, Hiroki Yamaue.   

Abstract

BACKGROUND: The aim of the present study was to identify the predicting factors for unresectability and to clarify who should receive precise evaluations for distant metastasis and locally advanced unresectability in patients with pancreatic ductal adenocarcinoma (PDAC).
METHODS: A total of 200 consecutive patients with PDAC who presented to the outpatient clinic between June 2009 and October 2012 were analyzed retrospectively. Clinical factors and the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, DUPAN-2 (pancreatic cancer-associated antigen) and CA 125 were analyzed.
RESULTS: Of the 200 patients who were investigated for PDAC, 60 (30%) were initially considered unresectable (15 patients with locally advanced tumors, 45 patients with distant metastases). Of the 136 (68%) patients who were surgically explored, 19 (9.5%) were detected to have minute metastases on laparotomy. A multivariate analysis revealed that tumor size (≥30 mm) and abnormalities in the levels of DUPAN-2 and CA 125 were independent predictors of unresectability (P = 0.002, 0.014, < 0.001, respectively). The patients with triple positive findings presented with the highest sensitivity (78.8%) for unresectability.
CONCLUSIONS: Patients with triple positive findings for a tumor size ≥30 mm, abnormalities in the levels of DUPAN-2 and CA 125 should receive precise evaluations for unresectability.
© 2014 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Carbohydrate antigen 125; Distant metastasis; Pancreatic ductal carcinoma; Tumor marker; Unresectability

Mesh:

Substances:

Year:  2014        PMID: 24764208     DOI: 10.1002/jhbp.109

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  2 in total

1.  A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion.

Authors:  Piotr Hogendorf; Aleksander Skulimowski; Adam Durczyński; Anna Kumor; Grażyna Poznańska; Aleksandra Oleśna; Joanna Rut; Janusz Strzelczyk
Journal:  Dis Markers       Date:  2017-03-05       Impact factor: 3.434

2.  Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.

Authors:  Xinchun Liu; Yue Fu; Qiuyang Chen; Junli Wu; Wentao Gao; Kuirong Jiang; Yi Miao; Jishu Wei
Journal:  BMC Gastroenterol       Date:  2018-11-06       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.